Johnson &amp; Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, marking the largest biotechnology merger since 2023 and the first biopharmaceutical merger exceeding $10 billion since 2024. Intra-Cellular's stock surged nearly 38% in pre-market trading, while Johnson &amp; Johnson's stock remained flat.
Risk Warning and Disclaimer
The market carries risks, and investment should be approached with caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk

Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion, making it the largest biotechnology merger and acquisition deal since 2023, and the first biopharmaceutical merger and acquisition exceeding $10 billion in 2024. Intra-Cellular's stock price rose nearly 38% in pre-market trading, while Johnson & Johnson's stock price remained unchanged

- Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, marking the largest biotech merger since 2023 and the first over $10 billion in 2024.  
- Intra-Cellular's stock surged nearly 38% in pre-market trading, while Johnson & Johnson's stock remained stable.  
- The article includes a risk warning, stating that market investments carry risks and do not constitute personal investment advice.